Merve Ecem Albayrak

Merve Ecem Albayrak

Auto-generated profile, based on publicly available information

Merve Ecem Albayrak

Izzet Baysal Devlet Hastanesi

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in Abant Medical Journal
Verified
Journal Article
Open access
PDF file
POPelin Oyardi
Pelin Oyardi
FDFunda Dağistanli
Funda Dağistanli
MAMerve Ecem Albayrak
Merve Ecem Albayrak
MEMustafa Ayhan Eki̇cİ
Mustafa Ayhan Eki̇cİ
Objective: To evaluate the prevalence of HPV and the risk of the cervical premalignant and malignant diseases in women with cervical erosion. Material and Methods: The results of 32649 women who were screened for cervical cancer between January 2014 and December 2019 were retrospectively analyzed. The results of HPV positive and HPV negative women with cervical erosion were compared. Kruskal-Wallis test and Chi-square test was used to compare of data between the groups. Results: Of the 32649 women who were screened for cervical cancer, 2566 had cervical erosion and 1585 (4.85%) had HPV positivity. HPV was found to be positive in 126 (4.91%) women with cervical erosion and no significant difference in the incidence of HPV positivity in asymptomatic women with and without cervical erosion (p=0.112). As in the general population, Hpv 16 and 18 were found to be most common in women with cervical erosions. Abnormal cervical cytology was found in 217 (0.72%) women without cervical erosion and 31 (1.21%) women with cervical erosion, which was significantly higher than in women without cervical erosion (p=0.045). There was no significant difference between those with and without cervical erosion in terms of CIN 1, CIN 2, CIN 3, LSIL, HSIL in situ cancer and total abnormal cervical pathology results. Conclusion: The incidence of HPV and the likelihood of cervical pathology in asymptomatic women with cervical erosion do not differ from the general population.

21 January 2025
Verified
Book
Open access
PDF file
SBSelda Bayat Balkan
Selda Bayat Balkan
SASertaç Ayçiçek
Sertaç Ayçiçek
ESEsra Söylemez
Esra Söylemez
UEUmut Erkök
Umut Erkök
GBGizem Berfin Uluutku Bulutlar
Gizem Berfin Uluutku Bulutlar
CUCan Ozan Ulusoy
Can Ozan Ulusoy

21 January 2025
Verified
Book Chapter
Closed access
MAMerve Ecem Albayrak
Merve Ecem Albayrak
Menopoz over aktivitesindeki kayıp sonucu menstrüasyonun kalıcı bir şekilde sonlandığı doğal bir dönemdir.. 12 aylık amenore sonrası dönem ise ‘’postmenopozal’’ dönem olarak adlandırılmaktadır (1). Endometriozis, pelvik ağrıya ve infertliteye neden olan rahim dışında endometriyal dokunun varlığı olarak tanımlanan hastalıktır. Genel olarak üreme döneminde görüldüğü bilinen endometriozisinpostmenopozal dönemde endometriozisprevalansının %2-5 olduğu bilinmektedir.Postmenopozalendometriozis için risk faktörlerine bakıcak olursak; Obezite, Artık OverSendromu , Cerrahi uygulamalarda overlerin in situ bırakılmasıdır. Endometriozisi olan postmenopozal kadınların kliniğe başvuru nedenlerine bakıldığında diğer yaş gruplarında olduğu gibi hiçbir şikayetin olmamasından hafif-ciddi ağrı yakınmalarına kadar geniş bir klinik spektrumla karşılaşırız.Tanı diğer yaş gruplarına benzer şekilde hastadan alınacak detaylı anamnez, muayene ve tetkiklerdir. Yapılan çalışmalara rağmen kesin tedavisi netleşmemiştir. Hastalarda tedavi seçeneğini seçerken; hastanın yaşı, klinik semptomları, eşlik eden ek patolojileri, çocuk istemi gibi bir çok durum birklikte değerlendirilerek karar verilmelidir. Postmenopozal hastaları değerlendirirken olası malignite riski de akıldan çıkarılmamalıdır.Postmenopozalendometriozis en sık olarak ağrı ve/veya over kitlesi olarak karşımıza çıkmaktadır. Menopoz döneminde endometriozisin cerrahi tedavisi, özellikle medikal tedaviye göre daha ön planda tutulmaktadır. Postmenopozalendometriozis nadir görülen bir durumdur, tedavisi cerrahidir. Cerrahiye uygun olmayan adaylar için aromataz inhibitörleri ve progesteron tedavisi rutin kullanıma girmemiştir. Açıklanmayan pelvik ağrısı olan postmenopozalendometriozis varlığının akılda tutulması gerekmektedir. Menopause is a natural period in which menstruation permanently ends as a result of loss of ovarian activity. The period after 12 months of amenorrhea is called the "postmenopausal" period (1). Endometriosis is a disease defined as the presence of endometrial tissue outside the uterus that causes pelvic pain and infertility. It is known that endometriosis, which is generally seen during the reproductive period, has a prevalence of 2-5% in the postmenopausal period.If we look at the risk factors for postmenopausal endometriosis; Obesity, Residual Ovary Syndrome, Leaving the ovaries in situ in surgical procedures. When we look at the reasons for applying to the clinic for postmenopausal women with endometriosis, we encounter a wide clinical spectrum, from no complaints to mild to severe pain complaints, as in other age groups. Diagnosis is a detailed anamnesis, examination and tests to be taken from the patient, similar to other age groups.Despite the studies, the definitive treatment has not been clarified. When choosing the treatment option in patients; The patient's age, clinical symptoms, accompanying additional pathologies, and desire to have children should be evaluated together to make a decision. The possible risk of malignancy should not be forgotten when evaluating postmenopausal patients. Postmenopausal endometriosis most commonly presents as pain and/or an ovarian mass. Surgical treatment of endometriosis during menopause is especially prioritized over medical treatment. Postmenopausal endometriosis is a rare condition, and its treatment is surgical. Aromatase inhibitors and progesterone therapy have not been routinely used for candidates who are not suitable for surgery. The presence of postmenopausal endometriosis with unexplained pelvic pain should be kept in mind.